Paul J Lytle's most recent trade in Actuate Therapeutics Inc. was a trade of 49,394 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Actuate Therapeutics Inc | Paul J. Lytle | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 49,394 | 49,394 | - | - | Employee Stock Option (right to buy) | |
| Actuate Therapeutics Inc | Paul J. Lytle | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 41,899 | 41,899 | - | - | Employee Stock Option (right to buy) | |
| Actuate Therapeutics Inc | Paul J. Lytle | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2024 | 234,971 | 0 | - | - | Non-Qualified Stock Options |